PBRM1 Deficiency Sensitizes Renal Cancer Cells to DNMT Inhibitor 5-Fluoro-2’-Deoxycytidine

Authors: Di Gu, Kai Dong, Aimin Jiang, Shaoqin Jiang, Zhibin Fu, Yewei Bao, Fuzhao Huang, Chenghua Yang, Linhui Wang

Source: Frontiers in Oncology, Vol 12 (2022)

Subject Terms: PBRM1 gene mutation, DNA methyltransferase inhibitor, renal cell carcinoma, FdCyd, synthetic lethality, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.870229/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/a37c57db70f94b1ba5f7283da875b202

Response of Metastatic Chordoma to the Immune Checkpoint Inhibitor Pembrolizumab: A Case Report

Authors: Xiaoli Wu, Xiangwu Lin, Ying Chen, Wencui Kong, Jinhe Xu, Zongyang Yu

Source: Frontiers in Oncology, Vol 10 (2020)

Subject Terms: chordoma, immunotherapy, PD-1, pembrolizumab, PBRM1 gene mutation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2020.565945/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/faed7c674c5b463890a2f564fce92b4e

This result is not displayed to guests.
Login for full access.